| CUE BIOPHARMA O.N. |
| USA |
| Gesundheit |
| US22978P2056 / A426PN |
| 1UC0 (Frankfurt) / CUE (NASDAQ) |
| FRA:1UC0, ETR:1UC0, 1UC0:GR, NASDAQ:CUE |
| - |
| https://www.cuebiopharma... |
|
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing precision immunotherapies for allergic and autoimmune diseases. Its current portfolio centers on therapeutic biologics designed to selectively modulate disease-sp..
>Volltext.. |
| 120.67 Mio. EUR |
| 113.17 Mio. EUR |
| 33.5 Mio. EUR |
| -87.54 Mio. EUR |
| -146.01 Mio. EUR |
| -24.02 EUR |
| 7.84 Mio. EUR |
| 15.47 Mio. EUR |
| -44.53 Mio. EUR |
| 0.82 |
| 368.67% |
| -335.2% |
| - |
| - |
| - |
| CUE BIOPHARMA, CUE BIO |
| 18.10.26 |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|